Award of five-year IDIQ for CTP- assessing tobacco-related clinical outcomes and human behaviors in tobacco
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75F40123D00039
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 3 $8,141,997 obligated
Award facts
- Opportunity
-
- 75F40123R00028 Solicitation number
- Combined order value
- $8,141,997 Current and potential, with all options
- Last date to order 62% complete
- IDV ceiling 33% used
- $25,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The Food and Drug Administration awarded a five-year Indefinite Delivery/Indefinite Quantity contract valued at $25 million to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization based in Albuquerque, New Mexico. This single-award, civilian contract, which commenced on September 26, 2023 and concludes September 29, 2028, supports the FDA's Center for Tobacco Products by assessing tobacco-related clinical outcomes and human behaviors in tobacco use and alternative nicotine delivery products. Lovelace Biomedical Research Institute brings substantial expertise in preclinical research services, including inhalation toxicology, animal studies, analytical testing, and disease model development, and has demonstrated extensive experience executing similar research initiatives for multiple federal agencies including the National Institutes of Health, Department of Defense, and Department of Health and Human Services.
Two task orders have been issued under this IDV vehicle to date. Task Order 1, valued at approximately $3.9 million and awarded September 27, 2023, evaluated biomarkers of exposure, biomarkers of potential harm, and health risk markers proportional to reductions in cigarette smoking upon switching to electronic nicotine delivery systems; however, this task order was terminated for convenience effective March 29, 2026, pursuant to Executive Order 14222 implementing government cost efficiency initiatives. Task Order 2, valued at $1.25 million and awarded September 29, 2023, examined the influence of synthetic cooling agents on cigarette sensory and subjective effects and use behavior. Both delivery orders are firm fixed-price contracts with performance locations in Calverton, Maryland, representing the government's strategic investment in evidence-based tobacco product research and regulatory science capabilities.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $5,000 |
Quick answers
Who was awarded contract 75F40123D00039?
75F40123D00039 was awarded to Lovelace Biomedical Research Institute by Food and Drug Administration (Department of Health and Human Services) on September 26, 2023.
How much is contract 75F40123D00039 worth?
Orders under 75F40123D00039 have obligated $8,141,997. 75F40123D00039's own ceiling is $25,000,000.
How many orders have been placed under contract 75F40123D00039?
3 orders have been placed under 75F40123D00039, the latest on September 14, 2026.
Who can order from contract 75F40123D00039?
75F40123D00039 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75F40123D00039 competed?
The extent of competition for 75F40123D00039 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV